Context Therapeutics enters $75M at-the-market equity offering with Leerink Partners

Context Therapeutics Inc.

ATM facility allows sale of up to $75M of common stock from time to time.
Leerink Partners receives 3.0% commission on gross proceeds; company reimburses certain expenses.
Net proceeds to fund R&D of product candidates and working capital / general corporate purposes.
Shares offered under effective S-3 filed Nov 2022; prospectus supplement dated Dec 2, 2024.
Company not obligated to sell any shares; agreement terminates upon full sale or earlier termination.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.